TWi Pharmaceuticals announced that it has received final approval from the Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Megestrol Acetate Suspension, the generic version of Par Pharmaceutical’s Megace ES.
Megace ES is a progestin indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS. It is intended to help improve appetite and gain weight. The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown.
Megestrol Acetate Suspension will be available in a 125mg/mL strength.
For more information visit TWiPharma.com.